|
Market Closed -
Nasdaq
04:00:00 12/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 22.79 USD | +1.15% |
|
-5.83% | - |
| 09-03 | Attovia Therapeutics Q2 Net Loss Widens | MT |
| 09-03 | Attovia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Attovia Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2026 | 2027 | 2028 |
|---|---|---|---|
| Market Cap 1 | 1,029 | - | - |
| Change | - | - | - |
| Enterprise Value (EV) 1 | 649.6 | 742.4 | 520.6 |
| Change | - | 14.3% | -29.88% |
| P/E | -8.11x | -10.8x | -9.24x |
| PBR | 2.74x | 3.79x | 2.44x |
| PEG | -0.1x | 0.4x | -0.6x |
| Capitalization / Revenue | 2,286x | - | - |
| EV / Revenue | 1,443x | - | - |
| EV / EBITDA | -7.22x | -6.19x | -3.71x |
| EV / EBIT | -7.17x | -6.19x | -3.68x |
| EV / FCF | -6.91x | -6.51x | -3.94x |
| FCF Yield | -14.5% | -15.4% | -25.4% |
| Dividend per Share 2 | - | - | - |
| Rate of return | - | - | - |
| EPS 2 | -2.779 | -2.096 | -2.437 |
| Distribution rate | - | - | - |
| Net sales 1 | 0.45 | - | - |
| EBITDA 1 | -89.96 | -119.9 | -140.3 |
| EBIT 1 | -90.61 | -120 | -141.3 |
| Net income 1 | -83.44 | -107.1 | -135.7 |
| Net Debt 1 | -379 | -286.1 | -507.9 |
| Reference price 2 | 22.53 | 22.53 | 22.53 |
| Nbr of stocks (in thousands) | 45,651 | - | - |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.11x | 1443.48x | -7.22x | - | 1.03B | |
| 20.07x | 7.08x | 14.22x | 1.48% | 68.24B | |
| 32.07x | 9.28x | 44.74x | 0.04% | 62.23B | |
| -77.91x | 15.04x | -72.53x | -.--% | 27.8B | |
| 28.78x | 6.1x | 15.83x | -.--% | 24.86B | |
| -14.55x | 5.23x | -6.58x | -.--% | 24.22B | |
| 26.34x | 4.96x | 16.5x | -.--% | 19.36B | |
| 49.79x | 18.37x | 37.27x | 0.3% | 17.28B | |
| 1249.7x | 36.02x | 786.01x | -.--% | 14.46B | |
| 17.74x | 5.28x | 12.34x | -.--% | 14.23B | |
| Average | 132.39x | 155.08x | 84.06x | 0.2% | 27.37B | |
| Weighted average by Cap. | 77.64x | 15.53x | 52.87x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ATTO Stock
- Valuation Attovia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
